Related references
Note: Only part of the references are listed.Cryo-EM structure of the prothrombin-prothrombinase complex
Eliza A. Ruben et al.
BLOOD (2022)
Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis
Wenman Wu et al.
HAEMATOLOGICA (2021)
Cryo-EM structures of human coagulation factors V and Va
Eliza A. Ruben et al.
BLOOD (2021)
Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy
James R. Fuller et al.
BLOOD (2021)
Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor
Joseph S. Gish et al.
BLOOD (2021)
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants
Benjamin J. Samelson-Jones et al.
BLOOD ADVANCES (2021)
A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
Henrik Ostergaard et al.
BLOOD (2021)
Haemophilia: factoring in new therapies
Hannah Fassel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A
Nhan H. Nguyen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Increased potency of recombinant VWF D′D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII
Jenny Chia et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach
Karina Winterling et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor
Estelle K. Ronayne et al.
FRONTIERS IN IMMUNOLOGY (2021)
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
Yesim Dargaud et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain
Ian W. Smith et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Unique surface-exposed hydrophobic residues in the C1 domain of factor VIII contribute to cofactor function and von Willebrand factor binding
Malgorzata A. Przeradzka et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice
Ekta Seth Chhabra et al.
BLOOD (2020)
Tolerating Factor VIII: Recent Progress
Sebastien Lacroix-Desmazes et al.
FRONTIERS IN IMMUNOLOGY (2020)
Factor VIII-driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry
Nadia Freato et al.
BLOOD (2020)
Discordance between platelet-supported and vesicle-supported factor VIII activity in the presence of anti-C2 domain inhibitory antibodies
Madhumouli Chatterjee et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
Shannon L. Meeks et al.
HAEMOPHILIA (2020)
Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor
Lisbeth Dagil et al.
BIOPHYSICAL JOURNAL (2019)
The von Willebrand factor D′D3 assembly and structural principles for factor VIII binding and concatemer biogenesis
Xianchi Dong et al.
BLOOD (2019)
A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
Vincent Muczynski et al.
BLOOD (2018)
FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity
Ruth A. Ettinger et al.
BLOOD ADVANCES (2018)
Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction
Philip M. Zakas et al.
NATURE BIOTECHNOLOGY (2017)
The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein
N. C. Leksa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A
Joerg Kahle et al.
BLOOD (2017)
A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII
Joshua Eubanks et al.
BLOOD (2016)
High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors
Glaivy Batsuli et al.
BLOOD (2016)
Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway
M. Monaghan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine
Gary E. Gilbert et al.
BLOOD (2015)
Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry
Po-Lin Chiu et al.
BLOOD (2015)
Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII
Andrew Yee et al.
BLOOD (2015)
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
Barbara A. Konkle et al.
BLOOD (2015)
Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody
Michelle E. Wuerth et al.
SCIENTIFIC REPORTS (2015)
Changes in the Factor VIII C2 domain upon membrane binding determined by hydrogen-deuterium exchange MS
Dionysios Pantazatos et al.
BIOCHEMICAL JOURNAL (2014)
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu et al.
BLOOD (2014)
Solution structure of the major factor VIII binding region on von Willebrand factor
Nuha Shiltagh et al.
BLOOD (2014)
A von Willebrand factor fragment containing the D′D3 domains is sufficient to stabilize coagulation factor VIII in mice
Andrew Yee et al.
BLOOD (2014)
Cofactor Activity in Factor VIIIa of the Blood Clotting Pathway Is Stabilized by an Interdomain Bond between His281 and Ser524 Formed in Factor VIII
Hironao Wakabayashi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit
Morgan Monaghan et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties
Lars Anders Svensson et al.
BIOLOGICAL CHEMISTRY (2013)
Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes
Justin D. Walter et al.
BLOOD (2013)
The diversity of the immune response to the A2 domain of human factor VIII
Rebecca C. Markovitz et al.
BLOOD (2013)
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis
Bernhard C. Lechtenberg et al.
BLOOD (2013)
Characterization and Solution Structure of the Factor VIII C2 Domain in a Ternary Complex with Classical and Non-classical Inhibitor Antibodies
Justin D. Walter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function
Junhong Lue et al.
BLOOD (2011)
Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII
H. Trent Spencer et al.
MOLECULAR THERAPY (2011)
Trp2313-His2315 of Factor VIII C2 Domain Is Involved in Membrane Binding STRUCTURE OF A COMPLEX BETWEEN THE C2 DOMAIN AND AN INHIBITOR OF MEMBRANE BINDING
Zhuo Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope
J. D. Dimitrov et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity
Henriet Meems et al.
BLOOD (2009)
The Factor VIIIa C2 Domain (Residues 2228-2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex
Tetsuhiro Soeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A
Christopher B. Doering et al.
MOLECULAR THERAPY (2009)
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Paolo Simioni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Structural Basis of the Cofactor- and Substrate-Assisted Activation of Human Coagulation Factor IXa
Thomas Zoegg et al.
STRUCTURE (2009)
Crystal structure of human factor VIII: Implications for the formation of the factor IXa-factor VIIIa complex
Jacky Chi Ki Ngo et al.
STRUCTURE (2008)
The tertiary structure and domain organization of coagulation factor VIII
Betty W. Shen et al.
BLOOD (2008)
The factor VIIIC1 domain contributes to platelet binding
Ting-Chang Hsu et al.
BLOOD (2008)
Antihuman factor VIIIC2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation
Shannon L. Meeks et al.
BLOOD (2007)
Identification of porcine coaglulation factor VIII domains responsible for high level expression via enhanced secretion
CB Doering et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
AJ Gale et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop
K Sichler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibitor development in previously untreated patients with hemophilia A: A prospective long-term follow-up comparing plasma-derived and recombinant products
W Kreuz et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2002)
Four hydrophobic amino acids of the factor VIIIC2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs
GE Gilbert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding factor X activating complex
FH Wilkinson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Factor IXa:factor VIIIA interaction -: Helix 330-338 of factor IX interacts with residues 558-565 and spatially adjacent regions of the A2 subunit of factor VIIIa
SP Bajaj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa
SW Pipe et al.
BLOOD (2001)
Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII
JA Kolkman et al.
BIOCHEMISTRY (2000)
Share Paper
